Evidence map›Paper›PMID 28280853›Full record

ArticleCancer immunology, immunotherapy : CII2017

Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis.

Daniel J Neitzke, Jacob S Bowers, Kristina Andrijauskaite, Nathaniel S O'Connell, Elizabeth Garrett-Mayer, John Wrangle, Zihai Li, Chrystal M Paulos, David J Cole, Mark P Rubinstein

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Advances in IL-7 Research on Tumour Therapy.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Daniel J NeitzkeDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Jacob S BowersDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Kristina AndrijauskaiteDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Nathaniel S O'ConnellDepartment of Public Health Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Elizabeth Garrett-MayerDepartment of Public Health Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
John WrangleDepartment of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Zihai LiDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Chrystal M PaulosDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
David J ColeDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Mark P RubinsteinDepartments of Surgery, and Microbiology and Immunology, Medical University of South Carolina, 86 Jonathan Lucas Street, Hollings Cancer Center Room 506, Charleston, SC, 29425, USA. markrubinstein@musc.edu.
MUSC Hollings Cancer Center · USMedical University of South Carolina · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Jian Ouyang · 2009 to 2026
$42.7M
TRAINING PROGRAM FOR MEDICAL SCIENTISTST32GM008716 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DEMORE, NANCY · 1999 to 2024
$9.3M
Project 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7M
MUSC/HCC Paul Calabresi Clinical Oncology Training Program PlanK12CA157688 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LOCKHART, ALBERT CRAIG, WRANGLE, JOHN M. · 2013 to 2022
$4.3M
Molecular chaperones and immune toleranceR01AI077283 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LI, ZIHAI · 2009 to 2021
$3.7M
Thrombocytes in Cancer ImmunityR01CA188419 · NCI · OHIO STATE UNIVERSITY · PI LI, ZIHAI · 2015 to 2019
$1.9M
Costimulatory mechanisms of antitumor Th17 cell immunityR01CA175061 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2013 to 2017
$1.5M
Defining and translating the properties that sustain the antitumor efficacy of Th17 cellsF30CA200272 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BOWERS, JACOB S · 2015 to 2018
$182k
NCI NIH HHS F30 CA200272NCI NIH HHS P01 CA186866NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA175061NCI NIH HHS R01 CA188419NIAID NIH HHS R01 AI077283NIGMS NIH HHS T32 GM008716
6 · The paper itself

Abstract

Adoptive cellular therapy (ACT) with the Th17 subset of CD4

Indexed as

AnimalsAntineoplastic AgentsApoptosisCD4-Positive T-LymphocytesCell ProliferationGene Expression RegulationImmunotherapy, AdoptiveInterleukin-15Interleukin-2Interleukin-7Interleukin Receptor Common gamma SubunitMelanoma, ExperimentalMiceTh17 CellsAntineoplastic AgentsInterleukin-15Interleukin-2Interleukin-7Interleukin Receptor Common gamma SubunitACTIL-15IL-2IL-7Th17 cells

Identifiers

PMID28280853
PMCPMC5679708
OpenAlexW2593462844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.